Leerink Partners Reiterates Outperform on Trillium Therapeutics (TRIL)

August 16, 2016 2:04 PM EDT
Get Alerts TRIL Hot Sheet
Price: $6.50 -2.99%

Rating Summary:
    4 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 21 | Down: 36 | New: 11
Trade TRIL Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Leerink Partners reiterated an Outperform rating and $20.00 price target on Trillium Therapeutics (NASDAQ: TRIL) as interest continues to build surrounding CD47 as an anti-cancer target. Private company Tioma Therapeutics announced today that it has raised $86M in Series A venture financing that will be used to further develop Tioma's antibody portfolio, including its lead candidate, an anti-CD47 antibody.

Analyst Michael Schmidt commented, "We are reiterating our OP rating on TRIL as interest continues to build in targeting CD47. We continue to view CD47 as a promising anti-cancer target in the tumor micro environment, although there are risks with respect to clinical translation. Private company Tioma Therapeutics announced today that it has raised $86M in Series A venture financing that will be used to further develop Tioma's antibody portfolio, including its lead candidate, an anti-CD47 antibody. We believe investors will continue to focus on TRIL's lead asset TTI-621 (CD47 inhibitor) with preliminary clinical data from the Phase I TTI-621 study expected at the American Society of Hematology (ASH, Dec. 3-6, 2016) Annual Meeting. Reiterate OP."

For an analyst ratings summary and ratings history on Trillium Therapeutics click here. For more ratings news on Trillium Therapeutics click here.

Shares of Trillium Therapeutics closed at $10.61 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments

Add Your Comment